Who is sponsoring NCT02772744?

NCT02772744 is sponsored by Zagazig University.

What drugs are being tested in NCT02772744?

Interventions in NCT02772744: Daclatasvir 60 MG Oral Tablet [Daklinza], Sofosbuvir 400 MG Oral Tablet [Sovaldi], Ribavirin Oral Product.

What condition does NCT02772744 study?

NCT02772744 studies Hepatitis C.

Is NCT02772744 still recruiting?

NCT02772744 is currently status unknown. Last updated 10 October 2017.

Last reviewed 2017-10-10 · How we verify

NCT02772744

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Determining the Sustained Virologic Response of Declatasvir in Egyptian Patients With Hepatitis C Virus Genotype 4

Status unknown Last updated 10 October 2017

What this trial tests

trial testing Daclatasvir 60 MG Oral Tablet [Daklinza] in Hepatitis C in 250 participants. Status unknown.

Timeline

1 November 2017

Primary endpoint
31 December 2018

31 December 2018

Quick facts

Lead sponsor	Zagazig University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	250
Start date	1 November 2017
Primary completion	31 December 2018
Estimated completion	31 December 2018

Drugs / interventions tested

Daclatasvir 60 MG Oral Tablet [Daklinza] — full drug profile →
Sofosbuvir 400 MG Oral Tablet [Sovaldi] — full drug profile →
Ribavirin Oral Product — full drug profile →

Conditions studied

Hepatitis C — all drugs for Hepatitis C →

Sponsor

Zagazig University

Who can join

18 and older, any sex, with Hepatitis C. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, cohort study in Faculty of Medicine, Zagazig University, Egypt. From June to December, 2016, investigators will follow up patients with chronic Hepatitis C virus genotype 4 receiving daclatasvir-sofosbuvir treatment regimen within the national program of Egyptian ministry of health and population. The primary outcomes are safety of the treatment and the sustained virologic response 12 weeks after discontinuation of therapy. For the secondary outcomes, investigators will measure the change in health related quality of life and investigate the genetic sequence of viral RNA of resistant patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Egypt's Premier Medical Student Research Group: A New Model for Medical Student Research in Developing Countries.
Negida AS. · · 2018 · cited 3× · PMID 30648093 · DOI 10.7759/cureus.3561

Verify or expand the search:

Other recruiting trials for Hepatitis C

Currently open trials in the same condition.

NCT06263829 — HCV Tappt Adherence Study · NA · recruiting
NCT06179498 — Partner Navigation Intervention for Hepatitis C Treatment Among Young People Who Inject Drugs · NA · recruiting
NCT06367465 — Feasibility and Acceptability of HCV Treatment in Pregnancy · recruiting
NCT05668780 — Buprenorphine Integration Research and Community Health · NA · active not recruiting
NCT05208697 — Tele-Harm Reduction · NA · active not recruiting

Other Zagazig University trials

Trials by the same sponsor.

NCT07423676 — Comparison Between Two Drugs in Sedation of Upper GI Endoscopy · not yet recruiting
NCT07418307 — Comparison Between Combined Biceps Femoris Short Head Block and Adductor Canal Block Versus Genicular Nerve Block · NA · not yet recruiting
NCT07435025 — Surgery for Obstructed Gastric Carcinoma · NA · active not recruiting
NCT07330375 — Effect of Intravenous Dexmedetomidine and Ketamine on Post-Operative Analgesia · Phase 3 · not yet recruiting
NCT07309731 — Impact OF Cooled Versus Thermal Radiofrequency Denervation In Management Of Chronic Lumber Facet Joint Pain · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02772744 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zagazig University
Last refreshed: 10 October 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02772744.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing